Radius Health (RDUS) Stock Price
Radius Health Price
Over the last 19 years Radius Health grew revenue by 6.3% annually, reaching 2.74 B USD. Earnings per share have grown at 1.5% per year over the last 17 years. For Radius Health, the net margin of -9.7% is down versus -0.2% a few years ago. At today's price the dividend yield works out to roughly 2.50%. The dividend has grown at 13.5% per year over the past 19 years. The consensus 12-month price target for Radius Health is 18.36 USD, about 38.8% below where the stock trades today. Of 8 analysts, 0 rate the stock a buy — an overall Hold consensus.
Radius Health stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Radius Health business model & stock analysis
Frequently asked questions about Radius Health
The business model of Radius Health Inc revolves around developing and commercializing innovative therapeutics to address unmet medical needs in the field of osteoporosis and other endocrine-related diseases. The company focuses on researching, developing, and marketing solutions that target the underlying causes of these conditions. By utilizing its expertise in hormone biology and technology platforms, Radius Health aims to provide patients with effective treatments that improve their overall health and quality of life. With a focus on delivering value and advancing scientific understanding, Radius Health Inc aims to be a leading player in the pharmaceutical industry.
Radius Health Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Radius Health Inc in the market include pharmaceutical companies such as Amgen Inc, Eli Lilly and Company, and Novartis AG.
Radius Health Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics in the field of osteoporosis and oncology. Founded in 2003, Radius Health Inc has established itself as a leader in the bone health market. The company's flagship product, TYMLOS®, is an FDA-approved therapy for postmenopausal women at high risk for fracture. With a strong team of experienced professionals and a robust pipeline of potential future treatments, Radius Health Inc continues to strive towards improving patient outcomes and addressing unmet medical needs in the areas of bone health and oncology.
Radius Health Inc has achieved significant milestones in its history. Some notable achievements include gaining FDA approval for their osteoporosis treatment drug, Tymlos, which has shown promising results in clinical trials. The company has also successfully expanded its market presence, solidifying partnerships with well-established pharmaceutical companies. Additionally, Radius Health Inc has made advancements in its research and development efforts, focusing on enhancing their product pipeline. These achievements demonstrate the company's commitment to providing innovative solutions for patients' healthcare needs.
Radius Health Inc is primarily present in the United States.
Radius Health Inc is a pharmaceutical company that is committed to improving the health and well-being of patients. With a strong corporate philosophy focused on innovation, research, and collaboration, Radius Health Inc strives to bring innovative and effective treatment options to the market. The company is dedicated to improving patient outcomes and providing value for both patients and shareholders. Through its dedication to research and development, Radius Health Inc aims to make a positive impact in the healthcare industry and contribute to the advancement of medical science.
Analysts currently set an average price target of 18.36 USD for the Radius Health stock (median: 18.36 USD), implying -38.8 % versus the latest price. The consensus is based on 8 analyst ratings.
7 analysts currently rate the Radius Health stock: 0 recommend buying, 4 holding and 3 selling. For 2026, analysts expect Radius Health to generate revenue of 3.03 B USD and earnings per share of 0.37 USD.
Converted at the current exchange rate, the Radius Health share trades at 26.82 EUR (30.00 USD).
The Radius Health share (RDUS) is listed on 4 stock exchanges, including: NASDAQ (RDUS), SIX (Zürich) (1R8.SW), Frankfurt (1R8.F), Düsseldorf (1R8.DU).
Radius Health Inc is a pharmaceutical company that specializes in researching, developing, and marketing medications for the prevention and treatment of osteoporosis. The company was founded in 2003 and is headquartered in Waltham, Massachusetts, USA. The business model of Radius Health includes three main divisions: research and development, sales and marketing, and partnerships and licensing. In the area of research and development, the company continuously works on developing new medications that meet the needs of patients with osteoporosis and other bone diseases. The latest scientific methods are used to deepen the understanding of these diseases and their causes. On the other hand, the sales and marketing department of Radius Health is responsible for bringing the already developed medications into the market. The company works closely with doctors, hospitals, and other healthcare facilities to ensure that the medications are used correctly by patients. In addition, public relations efforts are made to raise awareness of osteoporosis and other bone diseases and to emphasize the importance of preventive measures. The third division of Radius Health deals with partnerships and licensing. The company collaborates with other pharmaceutical companies and research institutions to create synergies and share research findings. The company also licenses its already developed medications to other companies for sale in specific markets. An important component of Radius Health's business model is the products it offers. The company's most well-known medication is TYMLOS, which contains the active ingredient Abaloparatide. By specifically targeting bone metabolism, TYMLOS can help reduce the risk of fractures in women with postmenopausal osteoporosis. Another product is the preparation BAQSIMI, which is used to treat severe hypoglycemic shock in diabetes patients. In summary, Radius Health's business model is focused on developing and bringing to market innovative and effective medications for the prevention and treatment of osteoporosis. Through targeted research and development, intensive sales and marketing efforts, and partnerships and licensing, the company aims to strengthen awareness of bone diseases, improve patients' quality of life, and become a leading company in the industry.
The expected revenue of Radius Health is 3.03 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Radius Health is 10.66 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Radius Health is currently 80.44. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Radius Health stock.
The price-to-sales ratio (P/S) of Radius Health is currently 0.28. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Radius Health stock.
The Eulerpool Quality Score for Radius Health is 1/10.
The ISIN of Radius Health is US7504692077. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Radius Health is A114VH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Radius Health is RDUS. The ticker symbol is used to trade Radius Health shares on the stock exchange.
Radius Health stock
Radius Health Peer Group
Radius Health Ticker
Radius Health FIGI
All fundamentals and in-depth analysis of Radius Health
Our stock analysis for Radius Health stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Radius Health. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.